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Aortic stenosis has been shown to share the same risk factors as
atherosclerosis which suggested a potential beneﬁt from statins
therapy. Fourteen studies which provided the effect of statins
treatment on aortic stenosis (AS) were meta-analyzed, including
5 randomized controlled trials (RCTs) and 9 observational studies.
In the RCTs, statins did not have any inﬂuence on peak aortic valve
velocity, peak valve gradient, mean valve gradient, aortic valve area
and aortic calciﬁcation compared to controls. In the observational
studies, the peak valve velocity, peak gradient and aortic valve area
showed less progression in the statins group compared to controls.
This article describes data related article title “The effect of statins
on valve function and calciﬁcation in aortic stenosis: a meta-ana-
lysis” (Zhao et al., 2016) [1].
& 2016 The Authors. Published by Elsevier Inc. This is an open
access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).Speciﬁcations tableubject area Clinical research, Meta-analysis
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Value of the data
 These data segregate the results of the randomized controlled trials (RCT) and the observational
studies that assessed the use of statins in patients with aortic stenosis.
 The data show clearly that the RCTs refuted any potential beneﬁt of statins in aortic stenosis in
contrast to the observational studies which showed potential slow progression, although not
consist.
 This clear discrimination should assist and guide future trials to better accurate ways for assessing
the effect of statins in aortic stenosis.
 Researchers might also be allowed in including our data analysis as part of future trials or meta-
analyses.1. Data
The data presented here showed the statins group (as a whole) had less increase in annual peak
valve velocity (p¼0.003), annual peak gradient (p¼0.006)). All these were only observed in obser-
vational studies (p¼0.002, po0.001) but not in RCTs (p¼0.48, p¼0.49). The annual mean gradient
showed no any signiﬁcant changes between statin and control groups (p¼0.05), and it was the case in
observational subgroup (p¼0.08) and in RCTs subgroup (p¼0.40) (Fig. 1). While, the statins group had
a trend of less changes in aortic valve area (p¼0.05) and less changes in aortic calciﬁcation (p¼0.03)
in observational subgroup but not in RCTs subgroup (p¼0.75 and p¼0,91) and in total (p¼0.09 and
p¼0.22) (Fig. 2).2. Experimental design, materials and methods
2.1. Design, materials and methods
We searched a medical database (PubMed) using the MeSH keywords (“aortic valve stenosis” and
“Hydroxymethylglutaryl-CoA Reductase Inhibitors”) together and in combination, having limited the
search to studies reported only in English prior to April 2015 and those which used adults Z19 years
of age. Fourteen studies were identiﬁed including 5 RCTs [2–6] and 9 observational studies [7–15].
The mean follow-up period of the studies ranged between 12 months and 5.6 years. Data from
patients commenced on statins were compared with controls and between subgroups.2.2. Statistical analysis
The data was extracted from each study and analyzed using the Revman software 5.3. The annual
changes in peak aortic velocity, peak and mean valve gradient, aortic valve area and aortic calciﬁ-
cation were compared between the statins group and the control group as well as the subgroups. A
po0.05 was deﬁned as statistical signiﬁcance.
Fig. 1. The statins group had less increase in annual peak valve velocity (p¼0.003) and peak gradient (p¼0.006) in total, and
this was only in observational studies but not in RCTs. The annual mean gradient did not show any signiﬁcant change in total
(p¼0.05), observationals and RCTs subgroups.
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Fig. 2. There was no difference between statins and non-statins treatment regarding the annual changes of aortic valve area
(p¼0.09),also it was the case between observational and RCTs subgroups. The annual increase of aortic valve calciﬁcation did
not show any signiﬁcant changes between statins and control groups (p¼0.22) and in RCTs subgroups, but it was not the case
in observational subgroups.
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